ENPP2 and pulmonary fibrosis: More recently, another ATX/lysoPLD inhibitor, GLPG1690, succeeded in halting the progression of idiopathic pulmonary fibrosis in Phase 2a clinical trials and it is now being tested in a Phase 3 trial [51].